Taryn Spiegel

📢 Join Syneos Health® for an insightful webinar where industry experts will unravel the complexities of early medical affairs engagement. 💡 Discover how small and mid-sized (#SMID) companies can strategically enhance their medical affairs planning, boosting asset valuation and thriving in competitive markets. Key Discussion Points: 🔍 Strategic Prioritization: Learn to maximize impact within budget constraints, ensuring each investment advances your medical affairs objectives. 🔍 Competitive Edge: Gain strategies to differentiate your brand in a competitive market, positioning your company and products for prominence. 🔍 Real-World Insights: Benefit from practical wisdom and expert guidance shared by industry leaders who have navigated similar challenges. 🔗 Learn more + register here: https://buff.ly/3yS66g1 🌟 Featured speakers: Anshu Sawhney Diego G. Rohan Gandhi #PharmaceuticalIndustry #MarketAccess #Commercialization #MedicalAffairs #Commercialization #HEOR #MarketAccess #PharmaceuticalMarketing

8

If you’re thinking about the fact that the FDA is requiring your study demographic to match the patient demographic of your indication (which you should), #RWD is required. Reach out to discuss the ways you can build a study that addresses both the concerns of the FDA, recruitment capabilities, and public health concerns

10

Have you heard of biosimilars as a treatment for Inflammatory Bowel Disease? Biosimilars are medications that closely replicate the structure and function of original biologic drugs.  How are #biosimilars approved and are they a safe and effective solution?  Chris Ma, MD, MPH, FRCPC answers all you need to know in our latest reel! Learn more about biosimilars as a treatment for IBD: https://lnkd.in/eAz7B7BJ #IBD #DigestiveHealth

22

The volume of clinical data has grown 183% over the last decade — impacting cycle times. 📈⏱️ For CROs already working under tight timelines, addressing the data chaos problem is imperative. Learn how elluminate can help 👇 The elluminate Clinical Data Cloud is a proven end-to-end platform that enables CROs to modernize trial processes, maximize efficiency and reduce cycle times. With elluminate, CROs can empower and engage clients with a single source of truth for clinical and operational data, facilitating streamlined data access for data management, clinical operations, medical monitoring and safety. Learn more about elluminate here: https://lnkd.in/e-mvhuAd #clinicaltrials #clinicaldata

26

Define the difference between Biosimilars and Generics with Tedra Gray, MSN, APRN, ACNP-BC! Tune into this FAQ to compare the composition of Biosimilars and Generic drugs at https://loom.ly/MYGBcZc 💊

9

1 Comment

At Colonis, we’re passionate about transforming everyday medicines into extraordinary opportunities. How? By adding value through innovative approaches.    Our latest thought leadership article dives deep into the world of value-added medicines, and showcases how we’re pushing boundaries to improve patient outcomes and healthcare efficiency. 🏥🔬    🌟 What’s inside?  👉 Continuous improvements with value-added medicines to make them more effective and user-friendly.  👉 The power of digital health and new drug-delivery systems.  👉 How Colonis is driving innovation in the value-added medicines space!    Discover the future of value-added medicines and Colonis' role in this exciting journey.    📖 Read the full article here: https://lnkd.in/eYUPQui9   #Innovation #Healthcare #ValueAddedMedicine #Colonis #ThoughtLeadership 

17

#ICYMI: #EYPT announced positive interim 16-week data for the ongoing Phase 2 #VERONA trial evaluating our investigational sustained delivery therapy in #DME.    Thank you to all involved in this clinical trial, including the site investigators, our internal team, and most importantly, patients. We look forward to sharing full topline data in Q1 2025 as we deliver on our commitment to improving the lives of patients living with serious #RetinalDiseases.      Read the full data results: https://lnkd.in/eqDZX2Fu     #InvestorNews 

45

1 Comment

Attention Pharma Commercial Leaders in the Northeast! Will we see you at the Pharma CX Tech Summit on November 14th in Princeton, NJ? We’re proud to sponsor this year’s event and excited to share how pharma is already using AI to drive meaningful results today. Join our VP of Industry Solutions and Strategic Alliances, Peter Harbin, as he and industry experts discuss: 1️⃣ The evolving role of field teams in customer experience 2️⃣ Using digital tools to improve HCP interactions 3️⃣ Customizing outreach based on HCP needs 📅 Panel Discussion: November 14th @ 2:20 PM 📍 The Nassau Inn, Princeton, NJ Visit our booth to see ODAIA's products in action! Seamlessly integrated into the field team's workflow, ODAIA equips reps with actionable insights to enhance HCP engagement at every stage. From territory-level predictive targeting and AI-driven call lists to GenAI-powered HCP insights, ODAIA supports commercial teams in executing informed, data-driven strategies for impactful HCP interactions. AI's role in pharma isn’t just theory; it’s delivering proven, measurable results. Discover how AI is driving brand success today! A big thanks to PanAgora Pharma for hosting this event and creating a platform to explore how AI and technology are reshaping customer experiences for patients and HCPs. #HCPEngagement #PharmaSales #PharmaCX #HCPExperience #CustomerScience #AIinPharma

35

8 Comments

When you have more than 30B data points, you can see what patients taking Repatha, Trulicity and other biologics say about adherence rates and more. Download (free): https://hubs.li/Q02J8b1S0

1

Payer policies can be unpredictable, but your biosimilar strategy doesn’t have to be. Amplify Rx's software streamlines the authorization process, ensuring that the right biosimilar is chosen every time. #HealthcareStrategy #HealthcareInnovation #Biosimilars #AmplifyRx

10

When you have more than 50B data points, you can see what patients taking Repatha, Trulicity and other biologics say about adherence rates and more. Download (free): https://hubs.li/Q02WXN0H0

5

☕ #Boston, grab you favorite Dunkin’ coffee and join us at the Precision in Clinical Trials Summit May 6 & 7! Stop by Booth #11 to meet the #IDDI experts Tara Kervin & Kalyn D. to discuss how IDDI’s solutions can assist your most pressing clinical trial challenges. 📈 Schedule a meeting today: https://lnkd.in/efjcJffp #PCTSummit #biometricscro #clinicaltrials #biostatistics #datamanagement #lifesciences #trialdesign

10

Dr. Paul Bunn discusses #pembrolizumab and its dominance in Lung Cancer Treatment. Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need; from the HCPs you want to hear from - even during busy congress season! #WorldLung #Oncology #LungCancer #Pembro

2

🚀 𝗧𝗵𝗲 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗶𝘀 𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴, and the 2024 ZS Medical Affairs Outlook Report highlights key trends shaping the field! 🔹 𝗛𝘆𝗯𝗿𝗶𝗱 𝗞𝗢𝗟 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁: Key Opinion Leaders now expect a mix of virtual and in-person interactions, reshaping MSL operations. 🔹 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝗠𝗦𝗟𝘀: Field medical roles, like MSLs, are expanding as organizations recognize their strategic value. 🔹 𝗔𝗜 & 𝗗𝗮𝘁𝗮 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀: Generative AI is transforming data insights and management. 🔹 𝗘𝗮𝗿𝗹𝘆-𝗣𝗵𝗮𝘀𝗲 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁: Building relationships with KOLs before Phase 3 trials is critical for product success. At The MSL Academy™, we're dedicated to guiding MSLs in embracing these changes and enhancing their impact on healthcare. 💡 #MedicalAffairs #MSL #AI #HealthcareLeadership #HybridEngagement #KOL #ClinicalResearch #medicalaffairs #KOLs #KOLEngagement #Pharma #Biotech #MSL #MedicalSacienceLiaison #medical #clinicalresearch #mslcareers

1

With innovative trial designs and cutting-edge technologies, the oncology clinical trial landscape is going through a huge transformation. New and advanced therapies continue to emerge, holding promise for many patients. In pharmaphorum's oncology deep dive issue, our VP of Oncology shares the top 5 trends to watch for in the oncology trial space. Read now: https://hubs.la/Q02FXzTy0 #Oncology #ClinicalTrials #ClinicalResearch #Cancer #CancerTrials

27

1 Comment

With innovative trial designs and cutting-edge technologies, the oncology clinical trial landscape is going through a huge transformation. New and advanced therapies continue to emerge, holding promise for many patients. In pharmaphorum's oncology deep dive issue, our VP of Oncology shares the top 5 trends to watch for in the oncology trial space. Read now: https://hubs.la/Q02QDf_m0 #Oncology #ClinicalTrials #ClinicalResearch #Cancer #CancerTrials

10